Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHA:600557)
China · Delayed Price · Currency is CNY 14.42
+0.17 (1.19%)
Feb 3, 2026, 3:00 PM CST
SHA:600557 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 3,101 | 3,865 | 4,840 | 4,323 | 3,614 | 2,985 |
Other Revenue | 32.75 | 32.75 | 24.28 | 27.46 | 34.95 | 47.42 |
| 3,134 | 3,898 | 4,864 | 4,351 | 3,649 | 3,032 | |
Revenue Growth (YoY) | -29.97% | -19.86% | 11.79% | 19.25% | 20.34% | -33.60% |
Cost of Revenue | 978.87 | 1,065 | 1,254 | 1,214 | 1,024 | 818.9 |
Gross Profit | 2,155 | 2,833 | 3,610 | 3,137 | 2,625 | 2,213 |
Selling, General & Admin | 1,424 | 1,853 | 2,287 | 2,057 | 1,745 | 1,456 |
Research & Development | 478.9 | 638.1 | 846.95 | 605.73 | 499.39 | 380.42 |
Other Operating Expenses | 56.78 | 51.6 | 66.74 | 73.07 | 60.8 | 4.29 |
Operating Expenses | 1,960 | 2,543 | 3,200 | 2,738 | 2,305 | 1,842 |
Operating Income | 194.96 | 289.98 | 409.65 | 399 | 320.11 | 371.33 |
Interest Expense | -11.93 | -22.3 | -22.48 | -1.91 | -11.15 | -23.47 |
Interest & Investment Income | 28.42 | 37.91 | 39.27 | 15.35 | 7.64 | 4.21 |
Currency Exchange Gain (Loss) | 0.15 | 0.15 | 0.06 | 0.15 | - | - |
Other Non Operating Income (Expenses) | -14.02 | -0.85 | -1.55 | -0.6 | -0.7 | -57.13 |
EBT Excluding Unusual Items | 197.57 | 304.9 | 424.95 | 411.99 | 315.89 | 294.95 |
Gain (Loss) on Sale of Assets | 0.81 | 1.09 | 0.76 | 1.38 | 0.97 | -0.3 |
Asset Writedown | -1.81 | -1.81 | -2.65 | -0.53 | -2.81 | -0.23 |
Other Unusual Items | 80.59 | 80.59 | 24.93 | 32.88 | 14.21 | - |
Pretax Income | 277.16 | 384.76 | 447.99 | 445.72 | 328.27 | 294.42 |
Income Tax Expense | -13.99 | 3.84 | 3.93 | 3.8 | 3.92 | 20.4 |
Earnings From Continuing Operations | 291.15 | 380.92 | 444.06 | 441.92 | 324.35 | 274.03 |
Minority Interest in Earnings | -9.77 | 10.94 | 20.1 | -7.45 | -3.81 | -11.1 |
Net Income | 281.38 | 391.86 | 464.16 | 434.47 | 320.54 | 262.92 |
Net Income to Common | 281.38 | 391.86 | 464.16 | 434.47 | 320.54 | 262.92 |
Net Income Growth | -33.76% | -15.57% | 6.83% | 35.54% | 21.92% | -48.14% |
Shares Outstanding (Basic) | 573 | 576 | 573 | 579 | 572 | 598 |
Shares Outstanding (Diluted) | 573 | 576 | 580 | 579 | 572 | 598 |
Shares Change (YoY) | -0.12% | -0.68% | 0.16% | 1.20% | -4.21% | 1.36% |
EPS (Basic) | 0.49 | 0.68 | 0.81 | 0.75 | 0.56 | 0.44 |
EPS (Diluted) | 0.49 | 0.68 | 0.80 | 0.75 | 0.56 | 0.44 |
EPS Growth | -33.68% | -15.00% | 6.67% | 33.93% | 27.27% | -48.84% |
Free Cash Flow | -21.21 | 225.8 | 661.03 | 784.85 | 736.77 | 510.78 |
Free Cash Flow Per Share | -0.04 | 0.39 | 1.14 | 1.35 | 1.29 | 0.85 |
Dividend Per Share | - | - | 0.372 | 0.220 | - | - |
Dividend Growth | - | - | 69.11% | - | - | - |
Gross Margin | 68.76% | 72.69% | 74.22% | 72.11% | 71.95% | 72.99% |
Operating Margin | 6.22% | 7.44% | 8.42% | 9.17% | 8.77% | 12.25% |
Profit Margin | 8.98% | 10.05% | 9.54% | 9.99% | 8.79% | 8.67% |
Free Cash Flow Margin | -0.68% | 5.79% | 13.59% | 18.04% | 20.19% | 16.85% |
EBITDA | 392.46 | 486.36 | 604.52 | 588.83 | 507.11 | 530.91 |
EBITDA Margin | 12.53% | 12.48% | 12.43% | 13.53% | 13.90% | 17.51% |
D&A For EBITDA | 197.5 | 196.38 | 194.88 | 189.83 | 187 | 159.58 |
EBIT | 194.96 | 289.98 | 409.65 | 399 | 320.11 | 371.33 |
EBIT Margin | 6.22% | 7.44% | 8.42% | 9.17% | 8.77% | 12.25% |
Effective Tax Rate | - | 1.00% | 0.88% | 0.85% | 1.19% | 6.93% |
Revenue as Reported | 3,134 | 3,898 | 4,864 | 4,351 | 3,649 | 3,032 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.